Cartesian Therapeutics, Inc. · NASDAQ:RNAC
Cartesian Therapeutics — Selecta Biosciences — American College of Rheumatology (ACR) Annual Meeting 2018
18 slides from Cartesian Therapeutics's conference presentation, Oct 23, 2018
Slide 1: SEL-212 Phase 2 Data Presented at ACR
SEL-212 Phase 2 Data Presented at ACR October 23, 2018
Slide 2: Safe Harbor / Disclaimer
Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the progress of the Phase 2 clinical trial of SEL-212 and expectations surrounding End-of-P
Slide 3: SEL-212 Executive Summary of Available Phase 2 Data
SEL-212 Executive Summary of Available Phase 2 Data • Evaluable patients who achieved 3-month of SUA control have maintained SUA control in months 4 and 5 of combination treatment • Projection for remaining patients in 5 dose cohorts suggest approximately 66% of evaluable patients could have SUA con
Slide 4: SEL-212 Clinical Development Plan
SEL-212 Clinical Development Plan DETERMINATION OF DOSE REGIMEN TO TAKE INTO PHASE 3 PHASE 3 PROGRAM WITH DEFINED DOSE REGIMEN Phase 1 a Phase 2 Dose Ranging Dose Finding Matrix approach to find pegadricase* best doses of the two 6 Monthly Combination Injections of SEL-212 (N= 22) components • 9 Coh
Slide 5: Phase 2 Combination Doses Data Projections Suggest 66% of Patients With Control of SUA
Phase 2, 5 Combination Doses Data Projections Suggest 66% of Patients With Control of SUA <6 mg/dL at 5 Months Pegadricase + SVP-Rapamycin SEL-212 1 0 0 Pegadricase 0.2 mg/kg 66% (21/32)* SVP-Rapamycin 5 0 0.1 or 0.15 mg/kg 0 0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 % mg/dLPts
Slide 6: Cohort 13: 0.15 mg/kg SVP-Rapamycin + 0.2 mg/kg pegadricase
Cohort 13: 0.15 mg/kg of SVP-Rapamycin + 0.2 mg/kg of pegadricase 0.15 0.15 0.15 0.15 0.15 SVP-Rapamycin Patient 1 0 0.2 0.2 0.2 0.2 0.2 pegadricase1 0 5 8 4 6 1 0 4 1 0 3 2 1 2 0 1 0 1 0 1 0 5 8 4 6 1 0 4 1 0 3 2 2 2 0 1 0 1 0 1 0 5 8 4 6 1 0 4 1 0 3 2 3 2 0 1 0 1 2 1 0 5 1 0 8 1 0 4 6 4 1 0 3 2 4
Slide 7: Cohort 15: 0.15 (1st)/0.1 (2nd-5th) mg/kg SVP-Rapamycin + pegadricase
Cohort 15: 0.15 (1st)/0.1 (2nd-5th) mg/kg of SVP-Rapamycin + 0.2 mg/kg of pegadricase 0.15 0.1 0.1 0.1 0.1 SVP-Rapamycin Patient 0.2 0.2 0.2 0.2 0.2 pegadricase 1 0 1 0 5 8 4 1 6 1 0 4 1 0 3 2 0 1 0 2 1 0 1 0 5 8 4 2 6 1 0 4 1 0 3 2 0 1 0 2 1 0 1 0 5 8 4 3 6 1 0 4 1 0 3 2 Anti 0 1 0 2 1 0 1 0 5 Week
Slide 8: Cohort 17: 0.1 mg/kg SVP-Rapamycin + 0.2 mg/kg pegadricase
Cohort 17: 0.1 mg/kg of SVP-Rapamycin + 0.2 mg/kg of pegadricase 0.1 0.1 0.1 0.1 0.1 SVP-Rapamycin Patient 0.2 0.2 0.2 0.2 0.2 pegadricase 1 0 1 0 5 8 4 6 1 0 4 1 0 3 1 2 0 1 0 2 1 0 5 1 0 8 1 0 4 6 4 1 0 3 2 2 0 1 0 2 1 0 1 0 5 8 4 6 1 0 4 1 0 3 3 2 0 1 0 2 1 0 1 0 5 Anti 8 4 6 1 0 Week 20 Evaluabl
Slide 9: DECT Scans Suggest Potential Reduction of Urate Burden in Phase 2 Study
DECT Scans Suggest Potential Reduction of Urate Burden in Phase 2 Study Number of Baseline Initial Urate Final Urate Patient Study Change in urate SUA Volume Volume # Drug volume (%) (mg/dL) (cm3) (cm3) • DECT(Dual Energy Computed Infusions Tomography) has been shown to 1 8.2 5 13.27 0.24 -98.19 be
Slide 10: Patient DECT Scan Images Show Reduction of Tissue Urate Burden
Patient 1 DECT Scan Images Show Reduction of Tissue Urate Burden Baseline Treatment Period 3 End of Study Total urate Total urate Total urate volume volume volume 13.27 cm3 1.83 cm3 0.24 cm3 0.15 mg/kg SVP-Rapa + ) 3 0.2 mg/kg pegadricase 0.2 mg/kg pegadricase ADA Titer 5 1 5 1 0 1 2 4 1 0 9 6 3 1 0
Slide 11: Observed Reduction in Flare Frequency in Combination Cohorts
Observed Reduction in Flare Frequency in 5 Combination Cohorts Has Been Consistent With Total Cohort Flare Data % of Patients in 5 Combination Dose Cohorts by Month e r 6 0 a 5 0 l P e g a d r i c a s e a l o n e F h S E L - 2 1 2 t i 4 0 3 5 w 3 4 s t n e i 2 0 t a 9 P 6 6 % 0 1 1 2 3 4 5 M o n t h
Slide 12: Interim Data Continue to Show Reduction in Flare Frequency During SEL-212 Therapy
Interim Data Continue to Show Reduction in Flare Frequency During SEL-212 Therapy % of Patients from All Cohorts Experiencing Flares by Month Severity of Flares 6 0 8 0 e 5 0 r a 64 l P e g a d r i c a s e a l o n e s F e 6 0 r h 4 0 S E L - 2 1 2 t a i l f w 2 9 f s 4 0 t 2 4 o 32 n e i 2 0 % t a 1
Slide 13: 5 Months Combination Treatment Has Not Shown Any Emerging Safety Signals
5 Months Combination Treatment Has Not Shown Any Emerging Safety Signals • SEL-212 has been generally well tolerated at clinically active doses for 5- combination dose cohorts following >130 administrations • 46 patients in 5-combination dose cohorts have been dosed in the Phase 2 study as of Octobe
Slide 14: Mitigation of IL-1β Production by SVP-Rapamycin in Preclinical Model of MSU-Induced Inflammation
Mitigation of IL-1β Production by SVP-Rapamycin in a Preclinical Model of MSU-Induced Inflammation • Monosodium urate crystals (MSU) Mitigation of MSU-induced inflammation in mice are known to cause inflammation by activating the NLRP3-inflammasome IL-1β Neutrophil exudate pathway resulting in IL-1β
Slide 15: Summary and Next Steps
Summary and Next Steps • Projections suggest approximately 66% of patients could have SUA control during 5 months of treatment with monthly dosing of SEL-212 • Low flare rates observed to date • Potential to rapidly eliminate tissue urate burden based on DECT imaging findings • 5 month combination t
Slide 16: Thanks to patients and clinical trial investigators
We thank all of the patients that have participated in our clinical program. We are very grateful to the clinical trial site investigators and their staff.
Slide 17: Appendix
See SELECTA josciences Appendix
Slide 18: SEL-212 Posters Presented at ACR
SEL-212 Posters Presented at ACR Monday, October 22, 2018; 9:00 AM - 11:00 AM • Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (pegadricase*) with SVP-Rapamycin Enables Sustained Reduction of Acute Gout Flares Tuesday, October 23, 2018; 9
Selecta Biosciences — American College of Rheumatology (ACR) Annual Meeting 2018 on 6ix